Novartis CEO Sees Recovery Ahead, Fueled By Pipeline And Alcon Growth
Novartis' half-year results show eye business Alcon and heart drug Entresto - which have been the two main sources of concern - are finally turning around, and its pipeline is firing on all cylinders towards a post-Gleevec recovery.
You may also be interested in...
There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.
Novartis, which is focused on securing bolt-on acquisitions rather than mega-M&A to bolster its pipeline, might have found the right target in French radiopharmaceutical company Advanced Accelerator Applications – if rumors are to be believed.
Prospects for Novartis' nAMD eye treatment brolucizumab rose on news the novel anti VEGF treatment met primary and key secondary endpoints in two Phase III studies compared to Eylea, using less dosing.